Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05243680




Registration number
NCT05243680
Ethics application status
Date submitted
8/02/2022
Date registered
17/02/2022
Date last updated
17/10/2023

Titles & IDs
Public title
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
Scientific title
A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744
Secondary ID [1] 0 0
212895
Universal Trial Number (UTN)
Trial acronym
AGILE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - GSK3511294 (Depemokimab)

Experimental: Participants diagnosed with asthma receiving GSK3511294 (Depemokimab) -


Other interventions: GSK3511294 (Depemokimab)
GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with adverse events (AEs) and serious adverse events (SAEs) over 52 weeks
Timepoint [1] 0 0
Up to Week 52
Primary outcome [2] 0 0
Number of participants with immunogenicity as measured by the presence of anti-drug antibody (ADA)/Neutralizing antibody (NAb) to GSK3511294 over 52 weeks
Timepoint [2] 0 0
Up to Week 52
Secondary outcome [1] 0 0
Annualized rate of clinically significant exacerbations over 52 weeks
Timepoint [1] 0 0
Up to Week 52
Secondary outcome [2] 0 0
Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score over 52 weeks (Scores on a scale)
Timepoint [2] 0 0
Baseline (Day 1) and Up to Week 52
Secondary outcome [3] 0 0
Change from Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) total score at Week 26 and Week 52 (Scores on a scale)
Timepoint [3] 0 0
Baseline (Day 1), Week 26 and Week 52
Secondary outcome [4] 0 0
Change from Baseline in pre-bronchodilator Forced expiratory volume in one second (FEV1) at Week 26 and Week 52 (Liters)
Timepoint [4] 0 0
Baseline (Day 1), Week 26 and Week 52

Eligibility
Key inclusion criteria
Inclusion criteria:

- Participants who completed the double-blind study intervention treatment during Study
206713 or Study 213744.

- Participants capable of giving signed informed consent/assent which includes
compliance with the requirements and restrictions listed in the informed consent form
(ICF) and in this protocol. In France, a participant will be eligible for inclusion in
this study only if either affiliated to or a beneficiary of a social security
category.
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Clinically significant change in health status during Study 206713 or Study 213744
which in the opinion of the investigator would make the participant unsuitable for
participation in this study.

- A current malignancy or a malignancy that developed during Study 206713 or Study
213744 (participants who had localized carcinoma of the skin that was resected for
cure will not be excluded).

- Participants who have other clinically significant medical conditions uncontrolled
with Standard of Care (SoC) therapy not associated with Asthma, for example (e.g.),
uncontrolled cardiovascular disease or ongoing active infectious disease which in the
opinion of the investigator makes them unsuitable for the study.

- Participants with known parasitic (helminth) infections within 6 months prior to Visit
1 will be excluded from the study or required to be adequately treated for helminth
infections before initiation of GSK3511294.

- Participants who meet the following based on results of Week 48 assessment from Study
206713 or Study 213744 or from a later result:

1. Alanine aminotransferase (ALT) greater than (>)2 times upper limit of normal
(ULN).

2. Total bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable
if bilirubin is fractionated and direct bilirubin less than [<] 35 percent [%]).

3. Cirrhosis or current unstable liver or biliary disease per investigator
assessment defined by the presence of ascites, encephalopathy, coagulopathy,
hypoalbuminemia, esophageal or gastric varices, persistent jaundice.

- Participants with current diagnosis of vasculitis. Participants with high clinical
suspicion of vasculitis at screening will be evaluated and current vasculitis must be
excluded prior to enrolment.

- Electrocardiogram (ECG) assessment: QTc corrected by Fridericia's formula (QTcF)
greater than or equal to (>=)450 milliseconds (msec) or QTcF >=480 msec for
participants with Bundle Branch Block at Visit 1.

- Current smokers.

- Participants with allergy/intolerance to the excipients of GSK3511294, a monoclonal
antibody, or biologic.

- Participants who are pregnant or breastfeeding. Participants should not be enrolled if
they plan to become pregnant during the time of study participation.

- Participants who for any reason permanently discontinued study treatment in the
previous study 206713/213744 will be excluded from this study.

- Other investigational product/clinical study:

1. Participants who have received treatment with an investigational agent (biologic
or non-biologic) within the past 30 days or 5 drug half-lives whichever is
longer, prior to the first dose, other than Study 206713/213744 study treatment.
The term "investigational" applies to any drug not approved for sale for the
disease/indication to treat in the country in which it is being used or
investigational formulations of marketed products.

2. Participants who are currently participating in any other interventional clinical
study.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
7/05/2025
Actual
Sample size
Target
637
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
GSK Investigational Site - Coffs Harbour
Recruitment hospital [2] 0 0
GSK Investigational Site - Adelaide
Recruitment postcode(s) [1] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Dakota
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
United States of America
State/province [16] 0 0
Wisconsin
Country [17] 0 0
Canada
State/province [17] 0 0
British Columbia
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
China
State/province [19] 0 0
Guangdong
Country [20] 0 0
China
State/province [20] 0 0
Jiangsu
Country [21] 0 0
China
State/province [21] 0 0
Liaoning
Country [22] 0 0
China
State/province [22] 0 0
Zhejiang
Country [23] 0 0
China
State/province [23] 0 0
Hangzhou
Country [24] 0 0
China
State/province [24] 0 0
Huhehaote
Country [25] 0 0
China
State/province [25] 0 0
Jinan
Country [26] 0 0
China
State/province [26] 0 0
Shanghai
Country [27] 0 0
Czechia
State/province [27] 0 0
Brno
Country [28] 0 0
Czechia
State/province [28] 0 0
Hradec Kralove
Country [29] 0 0
Czechia
State/province [29] 0 0
Jindrichuv Hradec
Country [30] 0 0
Czechia
State/province [30] 0 0
Olomouc
Country [31] 0 0
Czechia
State/province [31] 0 0
Strakonice
Country [32] 0 0
Czechia
State/province [32] 0 0
Tabor
Country [33] 0 0
Czechia
State/province [33] 0 0
Teplice
Country [34] 0 0
France
State/province [34] 0 0
Annecy Cedex
Country [35] 0 0
France
State/province [35] 0 0
Caen
Country [36] 0 0
France
State/province [36] 0 0
Cholet
Country [37] 0 0
France
State/province [37] 0 0
Marseille
Country [38] 0 0
France
State/province [38] 0 0
Strasbourg
Country [39] 0 0
Germany
State/province [39] 0 0
Hessen
Country [40] 0 0
Germany
State/province [40] 0 0
Rheinland-Pfalz
Country [41] 0 0
Germany
State/province [41] 0 0
Sachsen
Country [42] 0 0
Germany
State/province [42] 0 0
Berlin
Country [43] 0 0
Germany
State/province [43] 0 0
Bonn
Country [44] 0 0
Germany
State/province [44] 0 0
Hamburg
Country [45] 0 0
Germany
State/province [45] 0 0
Magdeburg
Country [46] 0 0
Hungary
State/province [46] 0 0
Gödöllo
Country [47] 0 0
Hungary
State/province [47] 0 0
Szigetvar
Country [48] 0 0
Italy
State/province [48] 0 0
Lazio
Country [49] 0 0
Italy
State/province [49] 0 0
Lombardia
Country [50] 0 0
Italy
State/province [50] 0 0
Sardegna
Country [51] 0 0
Italy
State/province [51] 0 0
Toscana
Country [52] 0 0
Japan
State/province [52] 0 0
Aichi
Country [53] 0 0
Japan
State/province [53] 0 0
Fukuoka
Country [54] 0 0
Japan
State/province [54] 0 0
Fukushima
Country [55] 0 0
Japan
State/province [55] 0 0
Hiroshima
Country [56] 0 0
Japan
State/province [56] 0 0
Hokkaido
Country [57] 0 0
Japan
State/province [57] 0 0
Kagawa
Country [58] 0 0
Japan
State/province [58] 0 0
Kagoshima
Country [59] 0 0
Japan
State/province [59] 0 0
Kanagawa
Country [60] 0 0
Japan
State/province [60] 0 0
Niigata
Country [61] 0 0
Japan
State/province [61] 0 0
Okayama
Country [62] 0 0
Japan
State/province [62] 0 0
Tokyo
Country [63] 0 0
Poland
State/province [63] 0 0
Gdansk
Country [64] 0 0
Poland
State/province [64] 0 0
Kielce
Country [65] 0 0
Poland
State/province [65] 0 0
Krakow
Country [66] 0 0
Poland
State/province [66] 0 0
Lodz
Country [67] 0 0
Poland
State/province [67] 0 0
Ostrowiec Swietokrzyski
Country [68] 0 0
Poland
State/province [68] 0 0
Rzeszow
Country [69] 0 0
Poland
State/province [69] 0 0
Wroclaw
Country [70] 0 0
Poland
State/province [70] 0 0
Zawadzkie
Country [71] 0 0
Spain
State/province [71] 0 0
Madrid
Country [72] 0 0
Spain
State/province [72] 0 0
Barcelona
Country [73] 0 0
Spain
State/province [73] 0 0
Basurto/Bilbao
Country [74] 0 0
Spain
State/province [74] 0 0
Benalmádena
Country [75] 0 0
Spain
State/province [75] 0 0
Gerona
Country [76] 0 0
Spain
State/province [76] 0 0
Granada
Country [77] 0 0
Spain
State/province [77] 0 0
Jerez de la Frontera
Country [78] 0 0
Spain
State/province [78] 0 0
Málaga
Country [79] 0 0
Spain
State/province [79] 0 0
Palma de Mallorca
Country [80] 0 0
Spain
State/province [80] 0 0
Santander
Country [81] 0 0
Spain
State/province [81] 0 0
Santiago de Compostela
Country [82] 0 0
Spain
State/province [82] 0 0
Valencia
Country [83] 0 0
Spain
State/province [83] 0 0
Zaragoza
Country [84] 0 0
Taiwan
State/province [84] 0 0
Kaohsiung
Country [85] 0 0
Taiwan
State/province [85] 0 0
New Taipei City
Country [86] 0 0
Taiwan
State/province [86] 0 0
Taichung
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Chertsey, Surrey
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Iqvia Pty Ltd
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this open-label 12-month extension study is to continue to characterize the
long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in
participants with severe asthma with an eosinophilic phenotype following completion of
clinical studies 206713 or 213744.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05243680
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US GSK Clinical Trials Call Center
Address 0 0
Country 0 0
Phone 0 0
877-379-3718
Fax 0 0
Email 0 0
GSKClinicalSupportHD@gsk.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05243680